company background image
UTH logo

United Therapeutics DB:UTH Stock Report

Last Price

€346.90

Market Cap

€15.4b

7D

1.0%

1Y

75.9%

Updated

29 Dec, 2024

Data

Company Financials +

United Therapeutics Corporation

DB:UTH Stock Report

Market Cap: €15.4b

UTH Stock Overview

A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. More details

UTH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 66.4% below our estimate of its fair value

Earnings are forecast to grow 9.67% per year

Earnings grew by 23.5% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

United Therapeutics Corporation Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€928.8m

Sartorius

XTRA:SRT3

€13.7b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.8b

Price History & Performance

Summary of share price highs, lows and changes for United Therapeutics
Historical stock prices
Current Share PriceUS$346.90
52 Week HighUS$381.20
52 Week LowUS$194.20
Beta0.55
1 Month Change-4.91%
3 Month Change9.12%
1 Year Change75.91%
3 Year Change81.62%
5 Year Change347.61%
Change since IPO1,827.22%

Recent News & Updates

Recent updates

Shareholder Returns

UTHDE BiotechsDE Market
7D1.0%3.1%0.5%
1Y75.9%-13.8%7.2%

Return vs Industry: UTH exceeded the German Biotechs industry which returned -13.8% over the past year.

Return vs Market: UTH exceeded the German Market which returned 7.2% over the past year.

Price Volatility

Is UTH's price volatile compared to industry and market?
UTH volatility
UTH Average Weekly Movement5.1%
Biotechs Industry Average Movement7.0%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: UTH has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: UTH's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,168Martine Rothblattwww.unither.com

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

United Therapeutics Corporation Fundamentals Summary

How do United Therapeutics's earnings and revenue compare to its market cap?
UTH fundamental statistics
Market cap€15.41b
Earnings (TTM)€1.07b
Revenue (TTM)€2.64b

14.5x

P/E Ratio

5.8x

P/S Ratio

Is UTH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UTH income statement (TTM)
RevenueUS$2.76b
Cost of RevenueUS$304.80m
Gross ProfitUS$2.45b
Other ExpensesUS$1.34b
EarningsUS$1.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)24.88
Gross Margin88.94%
Net Profit Margin40.31%
Debt/Equity Ratio6.6%

How did UTH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 07:32
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

United Therapeutics Corporation is covered by 37 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James BirchenoughBarclays
Derek TallerBenchmark Company